Inhibition of release of lentivirus particles with incorporated human influenza virus haemagglutinin by binding to sialic acid-containing cellular receptors

Valerie Bosch,¹ Beatrice Kramer,¹ † Tanya Pfeiffer,¹ Lilian Stärck¹‡ and David A. Steinhauer²

¹ Forschungsschwerpunkt Angewandte Tumorvirologie, F0200, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
² Division of Virology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK

Mutants of the haemagglutinin (HA) gene of human influenza virus A/Aichi/2/68 (H3N2) encoding HA proteins that are proteolytically cleaved intracellularly, defective in binding to cellular receptors or defective for acylation within the cytoplasmic C terminus have been generated. Here, the properties of these mutated HA molecules are described and their incorporation into the lipid membrane of released human immunodeficiency virus (HIV)-like particles is analysed. It is demonstrated that, when produced from cells coexpressing any of the binding-competent Aichi-HA molecules, release of HIV-like particles into the extracellular medium is reduced and the particles that are released fail to incorporate Aichi-HA. These blocks in release and incorporation, respectively, can both be overcome. The release of normal amounts of particles with incorporated HA can be achieved either by mutation of the receptor-binding site on the Aichi-HA molecule or by removal of sialic acid from surface proteins with neuraminidase. In contrast, as a result of blockage of the sialic acid-binding site by sialidated oligosaccharides on the HA itself, the HA of influenza virus A/FPV/Rostock/34 (H7N1) is efficiently incorporated into HIV-like particles. These results, namely that particle release can be inhibited by interactions between the incorporated glycoprotein and the cell surface and/or that interactions with other cellular components can be inhibitory to incorporation into retrovirus envelopes, probably reflect general principles that may hold for many viral and cellular glycoproteins.

Introduction

In recent years, numerous analyses have aimed to elucidate the processes that are important for the production and release into the extracellular medium of retrovirus particles that have incorporated a specific glycoprotein into their lipid membrane. These studies attempt to understand the process of glycoprotein incorporation into retroviruses in general, as well as using the principles revealed to achieve the incorporation of specific proteins of interest, such as those proteins necessary for retrovirus targeting. Protein incorporation is not specific to the homologous viral glycoprotein: many heterologous viral glycoproteins have been shown to be incorporated into retrovirus particles and to mediate infectivity in the appropriate host cells (pseudotyping). Additionally, and especially in the case of human immunodeficiency virus type 1 (HIV-1), numerous different cellular plasma membrane proteins have been demonstrated to be present in the retrovirus membrane (summarized by Bastiani et al., 1997). Although some cell surface glycoproteins appear to be preferentially incorporated (Arthur et al., 1992), evidence has also been reported that many cellular plasma membrane proteins can be incorporated into retrovirus envelopes without sorting (Hammarstedt et al., 2000). Thus, the amount of these proteins incorporated into the virus particle remains unclear and may simply reflect their relative concentration at the plasma membrane of the infected cell. On the other hand, viral glycoproteins appear to be
membranes. We have been interested in achieving the incorporation of, and eventually pseudotyping with, human influenza virus HA [A/Aichi/2/68 (H3N2), Aichi-HA] into virus particles: the atomic structure (Bullough et al., 1994; Wilson et al., 1981) as well as numerous defined mutants of Aichi-HA are available. Our long-term aim is to generate pseudotyped retrovirus particles with incorporated HA proteins that are functional in membrane fusion but lack the capacity to bind sialic acid. Targeting of pseudotyped particles to specific cells or tissue types could then be specified by alternative, coincorporated surface proteins. In order to manifest fusion activity, the HA molecule must be proteolytically cleaved into the disulphide-linked subunits HA1 and HA2. Human influenza virus HA molecules are not intracellularly processed, since there is only a single arginine residue at the proteolytic cleavage site between HA1 and HA2, whereas HA molecules with polybasic tracts at the HA1–HA2 junction are cleaved intracellularly in nearly all cell types. Thus, we have generated mutated Aichi-HA genes encoding potentially cleavable HA molecules, either with or without further mutations, leading to defective sialic acid receptor binding or affecting the cytoplasmic C-terminal cysteine residues implicated to influence raft localization. In this study, we describe the properties of these mutated Aichi-HA molecules, in particular, with respect to their incorporation into released HIV-like particles. Our findings indicate that, in contrast to FP-HA, HIV-like particles produced in cells coexpressing binding-competent Aichi-HA are released into the extracellular medium in reduced amounts and, further, that these released particles have failed to incorporate Aichi-HA. This situation could be overcome either by introducing mutations into Aichi-HA that abolish receptor binding or by removing sialic acid residues from cell surface proteins by treatment of cells with NA.

### Methods

**Constructs.** The cDNA sequence encoding the HA of influenza virus A/Aichi/2/68 (H3N2) was initially cloned into a Bluescript vector. The insertion of nucleotides encoding four additional arginines at the proteolytic cleavage site between HA1 and HA2 was carried out using standard PCR fusion techniques (Ho et al., 1989; Horton et al., 1989). The oligonucleotide used to insert the arginines was 5’-1011 GAATGTA-CCAGAAAACAAAACACTAGGAGGAAGAGGAGGTCTATTCGGCGCAATAG 3’. The numbers refer to the HA nucleotide positions, the letters in italics indicate the inserted nucleotides and the underlined letter indicates the position of an additional silent mutation, which destroyed an Shu restriction site and allowed mutant clones to be easily identified. The entire fragment generated by PCR was sequenced to confirm that only the desired nucleotide changes had been made. The cDNAs for the Aichi wild-type HA (Aichi-HA-Wt) and the derivative with the four inserted arginines (Aichi-HA-I4+ ) were then inserted into the eukaryotic expression vector pKEx (Rittner et al., 1991) to yield pKEx-Aichi-HA-Wt and pKEx-Aichi-HA-I4+, respectively. A fragment (A61 at position 1541 to a Pst site in the polymer linker downstream from the HA gene) encoding the C-terminal
cytoplasmic region of the mutated Aichi-HA with the changes C193M, C435A and C484Y (abbreviated MAY) (Lan et al., 1997) was exchanged for the same fragment in pKEx-Aichi-HA-I4 + to yield the derivative pKEx-Aichi-HA-I4 + /MAY. The mutations Y99F and L194A, described previously by Martin et al. (1998), which each alone very significantly reduce the ability of the HA receptor binding region to interact with the HA receptor, have been included to study their effects on membrane fusion. In combination with MAY, the HA receptor binding activity was almost completely abolished.

The HA receptors of the wild-type and mutant HA molecules were additionally cloned into the vaccinia virus transfer plasmid PB21 and recombinant vaccinia viruses expressing the mutated HA proteins were generated essentially as described previously (Blasco & Moss, 1995). The cDNA encoding the FP-HA protein was also cloned into pKEx to yield pKEx-FP-HA. An expression plasmid for bovine furin, pSG5new/bFur (Vey et al., 1994), referred to here as pFex-furin, and a plasmid containing the cDNA for the NA gene from influenza virus A/WSN/33 (H1N1) were kind gifts from H.-D. Klenk and W. Garten, University of Marburg, Germany. The cDNA for the NA gene was cloned into pKEx to yield pKEx-NA. pKEx-HIVΔenv, which encodes all of the HIV gene products except Env and Nef and leads to the release of non-infectious HIV-like particles, has been described previously (Henriksson & Bosch, 1998).

### Analyses of HA expression and incorporation into HIV-like particles

**Human 293T cells** (Pear et al., 1993), maintained in Dulbecco’s modified Eagle’s medium with 10% foetal calf serum, were transfected by standard calcium phosphate transfection procedures. Transfected cells were metabolically labelled with 75 μCi/ml [35S]methionine/ [35S]cysteine (Amersham) for 12 h from 36 to 48 h post-transfection (p.t.) in methionine/cysteine-depleted serum-free medium. When required, the labelling media were supplemented with 0.05 U/ml NA from *Vibrio cholerae* (Dade Behring). Labelled cells were lysed with 1% Triton-X-100 in PBS supplemented with protease inhibitor cocktail (Boehringer). After clarification, cell lysates were adjusted to 1% Triton-X-100, 0.5% deoxycholate and 0.1% SDS in PBS supplemented with protease inhibitor cocktail (RIPA buffer). Metabolically labelled HIV-like particles, released into the culture supernatants of cells transfected with pKEx-HIVΔenv3, were pelleted by centrifugation of the filtered media (45 μm pore-size filter) through a cushion of 32% sucrose, as described previously (Henriksson & Bosch, 1998; Henriksson et al., 1999). Pelleted materials were lysed in a small volume of 1% Triton-X-100 in PBS and either analysed directly by PAGE or adjusted to RIPA buffer detergent concentrations for immunoprecipitation. Immunoprecipitation was carried out, essentially as described previously (Pfeiffer et al., 1997), by employing polyclonal antisera from two mice immunized against the HA protein from the Aichi strain. The polyclonal rabbit anti-Aichi serum was kindly provided by H.-D. Klenk and W. Garten, University of Marburg, Germany. For this purpose, pKEx-furin, which encodes bovine furin (shown to be able to process influenza virus HA) (Vey et al., 1994), was employed. As shown in Fig. 2(A), Aichi-HA-I4+ was clearly proteolytically processed more efficiently in the presence of bovine furin, while Aichi-HA-Wt remained unprocessed.

### Antibody recognition, receptor-binding and membrane fusion activities

The cell surface expression levels and conformations of the wild-type and mutant HA molecules were analysed by ELISA using a panel of monoclonal antibodies (MAbS) against the respective recombinant vaccinia viruses, as described previously (Martin et al., 1998; Steinhauser et al., 1991). The assay for HA receptor-binding activity has also been described previously by Martin et al. (1998). Briefly, human erythrocytes loaded with horseradish peroxidase (HRP) were added to recombinant vaccinia virus-infected HeLa cells expressing the respective HA proteins. After washing, the concentration of HRP remaining was determined and the results corrected for HA expression, as established by ELISA using polyclonal rabbit anti-Aichi serum. The assay for membrane-fusion activity was also performed essentially as described previously (Martin et al., 1998). BHK-21 cells were infected with recombinant vaccinia viruses expressing the respective HA proteins and, at 15 h post-infection (p.i.), were treated with a low pH (5.0) buffer for 1 min. After neutralization, incubation was continued for 30 min and the cells were fixed, stained and photographed.

### Results

#### Expression and proteolytic processing of wild-type and mutated HA proteins

Fig. 1 illustrates the relevant features of the wild-type and mutant HA proteins used in this study. In common with all other human influenza virus HA proteins, the HA from the Aichi strain contains only a single arginine residue at the cleavage site between HA1 and HA2 and, thus, is not proteolytically processed intracellularly in the trans-Golgi network. In the case of another HA of the same subtype, influenza virus A/Port Chalmers/1/73, it has been demonstrated that a mutated HA protein with four arginine residues inserted at the cleavage site was efficiently processed intracellularly and was fusogenic after low pH treatment (Ohuchi et al., 1991). Thus, in order to more easily monitor intracellular transport and to generate a functional Aichi-HA protein in the absence of trypsin treatment, we generated pKEx-Aichi-HA-I4+, which has four arginine residues inserted at the cleavage site, and compared its expression to that of the wild-type construct pKEx-Aichi-HA-Wt and, additionally, pKEx-FP-HA, which encodes intracellularly cleavable FP-HA. Transfected 293T cells were metabolically labelled for approximately 12 h at 36–48 h p.t. and the respective HA molecules were immunoprecipitated from cell lysates and analysed by gel electrophoresis (Fig. 2). As expected, the FP-HA protein was intracellularly cleaved into HA1 (51 kDa) and HA2 (28 kDa) and only a minor band representing the HA precursor HA0 (80 kDa) could be detected (Fig. 2 A, lane 1). On the other hand, the precursor HA0 (82 kDa) from Aichi-HA-Wt was not proteolytically processed. In the case of the mutant Aichi-HA-I4+, HA1 (56 kDa) and HA2 (26 kDa) were clearly detected, indicating that the insertion of the four arginine residues had in fact generated a cleavage site for the cellular protease expressed in the 293T cells. However, in contrast to FP-HA, the relative amount of unprocessed HA0, in comparison to HA1 plus HA2, was much higher, indicating that intracellular cleavage was suboptimal (Fig. 2 A). Since efficient proteolytic processing is a prerequisite for HA function, we attempted to increase this by coexpressing an additional processing protease in cells expressing Aichi-HA-I4+. For this purpose, pEx-furin, which encodes bovine furin (shown to be able to process influenza virus HA) (Vey et al., 1994), was employed. As shown in Fig. 2(B), Aichi-HA-I4+ was clearly proteolytically processed more efficiently in the presence of bovine furin, while Aichi-HA-Wt remained un influenced. Quantification of the radio-
Fig. 1. Relevant features of the HA constructs employed. The HA proteins are shown as open bars, with a vertical line depicting the border between HA1 and HA2. Filled bars depict the membrane-spanning domain within HA2. The amino acid sequences at the cleavage site of the wild-type HA proteins are given, with the exact cleavage site indicated with an arrow. The approximate positions of N-linked oligosaccharides are shown by asterisks. The two oligosaccharides that affect receptor-binding of FP-HA are circled. The amino acid sequence at the cleavage site of the cleavable mutant Aichi-HA-I4 is shown with the inserted amino acids underlined. The positions of mutations within the cytoplasmic C-terminal domain of HA2 in Aichi-HA-I4/MAY are shown. The positions of the mutations that inhibit receptor binding are also shown for Aichi-HA-I4/DBM. In both Aichi-HA-I4/MAY and Aichi-HA-I4/DBM, the inserted arginines are indicated as +R4.

activity in respective bands revealed that the percentage of total HA in HA0 in comparison to HA1 plus HA2 was 44% in the absence, and 10% in the presence, of bovine furin. That is, in this latter case, the efficiency of proteolytic processing was similar to that observed when FP-HA was expressed (Fig. 2A, lane 1).

Incorporation of binding-competent HA proteins into HIV-like particles released into the extracellular medium

293T cells were transfected with expression vectors for the binding-competent HA proteins FP-HA, Aichi-HA-I4+ and Aichi-HA-I4+/MAY (the latter HA protein contains mutations at three cysteine residues in the cytoplasmic C terminus) in the presence or absence of HIV-like particle expression from pKEx-HVIAenv3. Expression of the respective HA molecules and of HIV-CA in transfected cells was confirmed both by immunofluorescence and by immuno-

precipitation (data not shown). The pelleted materials, generated by centrifuging the cultured supernatants through a cushion of sucrose, were analysed first by direct electrophoresis without prior immunoprecipitation. As shown in Fig. 3(A), HIV structural proteins (HIV-CA is the major component) were detected only in those samples in which pKEx-HVIAenv3 had been expressed. In the case of particles released from cells coexpressing FP-HA, radioactive bands representing FP-HA1 and -HA2 were detected in the absence of specific anti-HA
Table 1. Properties of the wild-type and mutant Aichi-HA molecules

(A) MAb reactivity

The reactivity of MAbs to intact cells expressing the mutant HA proteins by ELISA is shown. MAbs were designated previously by Daniels et al. (1983).

<table>
<thead>
<tr>
<th>Construct</th>
<th>HC3</th>
<th>HC31</th>
<th>HC68</th>
<th>HC100</th>
<th>HC263</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aichi-HA-Wt</td>
<td>1.188</td>
<td>0.686</td>
<td>0.551</td>
<td>0.487</td>
<td>0.386</td>
</tr>
<tr>
<td>Aichi-HA-I4</td>
<td>1.122</td>
<td>0.646</td>
<td>0.599</td>
<td>0.474</td>
<td>0.369</td>
</tr>
<tr>
<td>Aichi-HA-I4+/Y98F</td>
<td>1.453</td>
<td>1.132</td>
<td>1.335</td>
<td>0.701</td>
<td>0.638</td>
</tr>
<tr>
<td>Aichi-HA-I4+/L194A</td>
<td>1.087</td>
<td>0.792</td>
<td>0.577</td>
<td>0.427</td>
<td>0.356</td>
</tr>
<tr>
<td>Aichi-HA-I4+/DBM</td>
<td>0.964</td>
<td>0.659</td>
<td>0.446</td>
<td>0.400</td>
<td>0.266</td>
</tr>
</tbody>
</table>

(B) Human erythrocyte-binding assay

<table>
<thead>
<tr>
<th>Construct</th>
<th>Human erythrocyte binding (% of wild-type)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aichi-HA-Wt</td>
<td>100</td>
</tr>
<tr>
<td>Aichi-HA-I4</td>
<td>95.3</td>
</tr>
<tr>
<td>Aichi-HA-I4+/Y98F</td>
<td>0.8</td>
</tr>
<tr>
<td>Aichi-HA-I4+/L194A</td>
<td>0.4</td>
</tr>
<tr>
<td>Aichi-HA-I4+/DBM</td>
<td>0.0</td>
</tr>
</tbody>
</table>

immunoprecipitation. Fig. 3(B) shows the radioactive molecules, immunoprecipitated with the respective anti-HA sera, from lysates of the pelleted virus particles shown in Fig. 3(A). FP-HA1 and -HA2 components were clearly detectable. These results point to genuine incorporation of FP-HA into HIV-like particles, which is in line with previous reports that demonstrate the incorporation of FP-HA into avian and murine retroviruses (Dong et al., 1992; Hatzioannou et al., 1998). In contrast, immunoprecipitated, binding-competent Aichi-HA-I4+ or Aichi-HA-I4+/MAY could not be detected, even after a very long exposure of the gel to film. These results indicate that these components had failed to be incorporated in detectable amounts into the respective pelleted HIV-like particles. As already shown in Fig. 3(A) (compare the intensities of CA in lanes 1, 3 and 5), an additional effect of the coexpression of the binding-competent Aichi-HA-I4+ and Aichi-HA-I4+/MAY was a reduction in the amount of HIV-like particles released into the extracellular medium. Quantification of particle release by ELISA for HIV-CA revealed that, although somewhat variable, the amount of virus particles released from cells expressing Aichi-HA-I4+ or Aichi-HA-I4+/MAY was in the range of 20% of that released when pKEx-HIV\textnormal{Env3} was expressed either alone or with FP-HA (this did not differ significantly). This reduction was also observed, and, in fact, was more pronounced, on coexpression of non-cleavable Aichi-HA-Wt (Table 2).

Further properties of cleavable Aichi-HA-I4+ and of binding-incompetent Aichi-HA-I4+/DBM

Based on the crystal structure of Aichi-HA-receptor analogue complexes, Aichi-HA mutants with single amino acid changes predicted to inhibit sialic acid binding have been generated and analysed. Several of these mutations severely impaired binding. However, the results of a sensitive infectivity assay demonstrated that this impairment was not complete (Martin et al., 1998). With the aim of completely abolishing receptor-binding, two of these mutations, Y\textsuperscript{*}F and L\textsuperscript{*}A, each of which severely impairs binding, were introduced together into the cDNA sequence encoding Aichi-HA-I4+. The mutated gene product is referred to as Aichi-HA-I4+/DBM. In an initial assay, we determined if the different HA molecules were expressed at the cell surface and if they were reactive with a panel of five MAbs, each of which recognizes a different conformational determinant on the Aichi-HA protein. As shown in Table 1(A), binding of all of the MAbs to intact recombinant vaccinia virus-infected cells expressing Aichi-HA-Wt and Aichi-HA-I4+ was virtually identical, demonstrating that the insertion of the four arginine residues at the cleavage site had no detectable effect on the conformation of the HA. This was also the case for Aichi-HA-I4+/L194A. On the other hand, binding of all of the MAbs to cells expressing Aichi-HA-I4+/Y98F and Aichi-HA-I4+/DBM was slightly...
higher and slightly lower, respectively, than to Aichi-HA-Wt (Table 1A). However, since all of the MAbS reacted with both constructs, the differences in binding probably reflect differences in cell surface expression rather than effects of mutations on the antigenic structure of any specific region of the respective molecules.

The receptor-binding activities of the different Aichi-HA molecules were determined in an erythrocyte-binding assay. As shown in Table 1(B), cells expressing Aichi-HA-I4 + bind erythrocytes equally well as those expressing Aichi-HA-Wt. As has been demonstrated previously (Martin et al., 1998), the mutations Y98F and L194A (here in the context of Aichi-HA-I4 +) virtually abolish erythrocyte binding and marginal values, only slightly higher than the background values, were measured. In the case of Aichi-HA-I4+/DBM, no erythrocyte binding could be detected.

Since it is known that, in the absence of receptor-binding, close proximity of the target membrane is sufficient to allow low pH-induced membrane fusion, we tested the abilities of the different HA molecules to mediate polykaryon formation after low pH treatment. All of the cleavable HA molecules, but not the vaccinia virus alone (Steinhauer et al., 1999) (data not shown), whether competent at binding or not, did, indeed, induce polykaryon formation in BHK-21 cells. This is shown in Fig. 4 for Aichi-HA-I4+ and Aichi-HA-I4+/DBM. Although clear syncytia can be observed in the case of the binding-defective Aichi-HA-I4+/DBM, these syncytia are less pronounced in comparison to those induced by the binding-competent Aichi-HA-I4+. This may be a result of the lack of receptor binding and/or may be due to the slightly poorer cell surface expression observed by binding of the MAbS (Table 1A).

Incorporation of binding-defective Aichi-HA into HIV-like particles

293T cells were transfected with pKEx-Aichi-HA-I4+/DBM or pKEx-FP-HA in the presence or absence of pKEx-HIVΔEnv3. In a further culture, pEx-furin was cotransfected with pKEx-Aichi-HA-I4+/DBM and pKEx-HIVΔEnv3. As shown in Fig. 5(A), cellular expression of Aichi-HA-I4+/DBM was approximately equal, independent of coexpression of HIV-like particles and bovine furin. In the presence of bovine furin, proteolytic processing of HA into HA1 and HA2 in cell lysates was again increased (Fig. 5A, compare lanes 2 and 3). HIV-CA was immunoprecipitated in approximately equal amounts only from samples in which pKEx-HIVΔEnv3 had been coexpressed (Fig. 5A, lower panel). Fig. 5(B) shows direct PAGE (no prior immunoprecipitation) of enriched HIV-like particles released from the respective cultures. HIV proteins could only be observed when pKEx-HIVΔEnv3 had been expressed. Quantification of HIV-CA by ELISA demonstrated that, in contrast to the coexpression of the binding-competent Aichi-HA molecules, coexpression of Aichi-I4+/DBM did not result in a reduction in the release of HIV-like particles. In addition to the protein bands present in all of the pelleted virus preparations, radioactive bands at the positions of Aichi-HA0 and -HA1 (on expression of Aichi-HA-I4+/DBM without bovine furin), Aichi-HA1 (on expression of Aichi-HA-I4+/DBM with bovine furin) and FP-HA1 plus -HA2 (on expression of FP-HA) were observed. This indicated that these HA molecules had been incorporated. The possible presence of Aichi-HA2 (26 kDa) could not be analysed as it was not separated from HIV-CA (24 kDa). Immunoprecipitation of HA molecules from enriched HIV-like particles is shown in Fig. 5(C). It can now be seen more clearly that, in the absence of bovine furin, Aichi-HA-I4+/DBM HA0, HA1 and HA2 had been incorporated, whereas HA1 and HA2 were the predominant incorporated molecules in the presence of bovine furin. No HA-specific bands were observed in the absence of HIV-like particle expression. This experiment clearly demonstrated that, in contrast to the binding-competent Aichi-HA proteins analysed in Fig. 3, Aichi-HA-I4+/DBM could be efficiently incorporated into HIV-like particles. Since in the presence of bovine furin, predominantly cleaved HA1 and HA2 exit the cell in released HIV-like particles, this at least partially explains why the change in the intracellular ratio of HA0 to HA1 plus HA2 (Fig. 5A), in the presence of furin, was not as dramatic as that observed in Fig. 2. In this latter case, expression of intracellular Aichi-HA-I4+ had been analysed in the absence of HIV-like particles. It is important to note that in the absence, but not in the presence, of coexpressed bovine furin, mixtures of HA-trimers containing both processed and unprocessed HA molecules may exist in the retrovirus envelope and are probably inhibited in HA function.

Effect of NA on incorporation of binding-competent HA proteins into HIV-like particles

By analogy to the situation with NA-defective influenza virus (Liu et al., 1995), we considered the possibility that interactions with sialated surface proteins were resulting in the reduced release of HIV-like particles with incorporated
Inhibition of lentivirus particle release

**Fig. 5.** Incorporation of binding-incompetent Aichi-HA-I4+/DBM into HIV-like particles. Metabolically labelled 293T cells cotransfected with pKEx-Aichi-HA-I4+/DBM (lanes 1–3) or pKEx-FP-HA (lane 4), either with (+) or without (−) pKEx-HIVΔEnv3 (lanes 1, 3 and 4; designated CA) and pEx-furin (lane 3). (A) PAGE of HA (upper panel) and HIV-CA (lower panel) immunoprecipitated from lysates of transfected cells. (B) Direct PAGE (no prior immunoprecipitation) of centrifuged pellets from the culture supernatants of transfected cells. Asterisks highlight the positions of incorporated HA proteins. (C) PAGE of HA proteins immunoprecipitated from the lysates of the centrifuged pellets analysed directly in (B). The positions of the relevant HA and HIV proteins are shown on the left. Molecular mass markers are shown on the right.

**Table 2.** Effect of NA on the release of HIV-like particles from cells coexpressing Aichi-HA

<table>
<thead>
<tr>
<th>Construct</th>
<th>Without NA</th>
<th>With NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aichi-HA-I4+/DBM</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Aichi-HA-I4+</td>
<td>28</td>
<td>100</td>
</tr>
<tr>
<td>Aichi-HA-I4+/MAY</td>
<td>28</td>
<td>110</td>
</tr>
<tr>
<td>Aichi-HA-Wt</td>
<td>1</td>
<td>72</td>
</tr>
</tbody>
</table>

The amount of HIV-like particles released into the medium of transfected cells treated either with or without soluble NA between 36 and 48 h p.t. was quantified by ELISA for HIV-CA. The amount of virus particles released from cells coexpressing Aichi-HA-I4+/DBM was taken as 100%.

binding-competent Aichi-HA and, additionally, were responsible for the fact that those particles that were released did not reveal detectable incorporation of the binding-competent Aichi-HA molecules. To examine this, we added bacterial NA, which removes sialic acid from glycoproteins and glycolipids, during metabolic labelling. The first observation that we made was that the addition of NA resulted in an increase in the amount of HIV-like particles released from cells coexpressing binding-competent Aichi-HA. As illustrated in Table 2, in the presence of NA, the amounts of HIV-like particles released were now approximately equivalent to those released from cells expressing pKEx-HIVΔEnv3 alone or coexpressing Aichi-HA-I4+/DBM. This was also the case on coexpression of Aichi-HA-Wt, which, in the absence of NA, had virtually completely abolished HIV-like particle release. Fig. 6 shows the Aichi-HA components immunoprecipitated from lysates of pelleted particles produced in the presence of soluble NA. The binding-competent Aichi-HA-Wt, Aichi-HA-I4+ and Aichi-HA-I4+/MAY proteins were incorporated into enriched HIV-
HIV-like particles that have efficiently incorporated binding-acid-containing cellular-binding partners allows the release of I4 coexpressed from pKEx-NA. This is illustrated for Aichi-HA-I4 was also observed if, instead of adding soluble NA to the culture medium, the NA gene from influenza virus WSN was coexpressed from pKEx-NA. This is illustrated for Aichi-HA-I4 + in Fig. 6. It can be seen again (Fig. 6, lane 6) that, in the absence of NA, Aichi-HA-I4 + /MAY is not incorporated into released virions. These results show that destruction of sialic acid-containing cellular-binding partners allows the release of HIV-like particles that have efficiently incorporated binding-competent Aichi-HA molecules.

**Discussion**

Due to the availability of detailed structural information, the Aichi-HA glycoprotein, and defined variants thereof, represent interesting candidates for pseudotyping retrovirus vectors. Two absolute requirements for functional pseudotyping are proteolytic processing and incorporation of the HA into the retrovirus envelope, issues which have been addressed in this study. By analogy to a similar mutant generated in the HA gene of the related human influenza virus A/Port Chalmers/1/73 (Ouchchi et al., 1991), we generated the potentially cleavable variant Aichi-HA-I4 +, which has four arginine residues inserted at the cleavage site. However, proteolytic processing of this variant in 293T cells, although clearly detectable, was suboptimal (Fig. 2A); proteolytic processing could not be increased by the introduction of another arginine residue at the cleavage site (designated Aichi-HA-I5 +; data not shown). However, on coexpression of bovine furin, cleavage of Aichi-HA-I4 + was substantially improved and reached levels comparable to those observed for avian FP-HA. Thus, the suboptimal cleavage observed on expression of Aichi-HA-I4 + alone was due neither to inadequate intracellular transport nor to inaccessibility of the cleavage site. In fact, additional analyses with a panel of MAbs also confirmed unimpeded cell surface expression and correct conformation (Table 1A). Thus, suboptimal cleavage is more likely to be the result of poor recognition of the Aichi-HA-I4 + cleavage site by the processing enzymes endogenously expressed in 293T cells. The proteolytic processing properties of the variant Aichi-HA-I4 + /MAY, in which the three palmitoylated cysteine residues in the cytoplasmic tail of the HA protein had been mutated, were indistinguishable from those of Aichi-HA-I4 +. The mutation of these residues in the context of Aichi-HA-W1 does not affect the ability of the Aichi-HA to form heterokaryons and, in reverse genetic experiments, the mutated HA protein is incorporated into infectious viruses (Lin et al., 1997; Zhang et al., 2000).

The binding-defective mutant Aichi-HA-I4 + /DBM generated in this study carries two amino acid changes, Y98F and L194A, each of which individually significantly inhibits binding to cellular receptors (Martin et al., 1998). These amino acid changes have not led to protein misfolding (Table 1) and proteolytic processing is the same as that observed for Aichi-HA-I4 +. Further proof of protein integrity is the fact that, despite the complete lack of detectable receptor binding (Table 1B), Aichi-HA-I4 + /DBM was functional in inducing membrane fusion after low pH treatment (Fig. 4). This demonstrated, as has also been shown by others (Ellens et al., 1990; Schoen et al., 1996; Wharton et al., 1986), that proximity to the target membrane (in this case of a neighbouring BHK-21 cell) is sufficient to allow low pH-induced membrane fusion in the absence of sialic acid receptor binding.

Coexpression of any of the binding-competent Aichi-HA molecules in cells transfected with the HIV particle expression vector pKEx-HIVΔEnv3 led to a reduction in the quantity of HIV-like particles released (Table 2). In the cases of Aichi-HA-I4 + and Aichi-HA-I4 + /MAY, however, particle release was clearly still occurring (it was about 20% compared to that observed in the absence of HA), but the particles that were released did not reveal any detectable incorporated HA molecules. In contrast, the extent of HIV-like particle release was normal on coexpression of the binding-defective mutant Aichi-HA-I4 + /DBM and returned to normal when cells expressing any of the binding-competent HA molecules were treated with soluble NA from V. cholerae. In these latter cases, the released particles also revealed efficient incorporation of the respective Aichi-HA proteins. On the one hand, these results strongly support the concept that interactions between binding-competent Aichi-HA and other sialic acid-containing components are the reason for the reduction in particle release. On the other hand, they also explain the lack of incorporation of Aichi-HA molecules in the remaining released particles. Liu et al. (1995) have reported similar findings with NA-deficient influenza virus. They could demonstrate that, in the lack of NA, influenza virus particles remain associated with the infected cell, to some extent, as aggregates at the cell surface and, to some extent, after re-entry, as aggregates within intracellular vesicles. The association of these influenza viruses with the cell is a consequence of an association of the HA protein in virions with other sialic acid molecules, these being other HA molecules, with resulting virus aggregation, or sialic acid-containing cellular receptors. Virus release and infectivity could be restored by the addition of soluble NA to the extracellular medium. It is very likely that the same phenomenon is responsible for the reduction in HIV-like particle release from cells expressing binding-competent Aichi-HA. In other words, virions that are potentially releasable, which presumably contain incorporated binding-competent Aichi-HA, remain associated with the cell and are not found in the extracellular medium unless NA, either coexpressed in the cell or in a soluble form in the medium, is present. The fraction of particles in the extracellular media of cells coexpressing Aichi-HA-I4 + or Aichi-HA-I4 + /MAY are presumably released since they have failed to incorporate detectable amounts of the
Inhibition of lentivirus particle release

We thank Steve Wharton, MRC, Mill Hill, London, UK for assistance in the erythrocyte-binding assay and H.-D. Klenk and W. Garten, both from the University of Marburg, Germany, for bovine furin and WSN neuraminidase plasmids as well as interferon against the HA of influenza virus A/FPV/Rostock/34 (H7N1).

References


Henriksen, P., Pfeiffer, T., Zentgraf, H., Alke, A. & Bosch, V. (1999). Incorporation of wild-type and C-terminally truncated human epidermal respective binding-competent Aichi-HA. We can only speculate in general terms as to the reason for this lack of incorporation. It is conceivable that the released particles have budded from regions of the membrane that per se lack binding-competent Aichi-HA. Alternatively, it may be that interactions with certain sialic acid-containing cellular molecules may have resulted in a segregation of the binding-competent Aichi-HA molecules away from the budding site of that fraction of particles that are still released.

As shown in Table 2, non-cleavable Aichi-HA-Wt results in a more pronounced inhibition of HIV-like particle release than the cleavable Aichi-HA-I4+ and Aichi-HA-I4+/MAY. We do not have an explanation for this. Although one could speculate that more avid binding to sialic acid-containing molecules could account for this difference, we did not observe any differences in receptor binding, as measured in an erythrocyte-binding assay (Table 1A). The three palmitoylated cysteine residues in the cytoplasmic tail of the HA protein, which have been mutated in Aichi-HA-I4+/MAY, have been reported to reduce the association of Aichi-HA with glycolipid-enriched membrane rafts (Melkonian et al., 1999; Zhang et al., 2000). However, in the presence of NA, the extent of incorporation appeared to be comparable to that observed with Aichi-HA-I4+, indicating that the altered localization has not affected incorporation.

The fact that FP-HA was incorporated into HIV-like particles is consistent with the previously reported efficient incorporation of FP-HA into the membrane of released avian and murine retroviruses (Dong et al., 1992; Hatziioannou et al., 1998). However, in light of the results with the binding-competent Aichi-HA molecules shown in this study, an open question remains as to why this is the case. Ohuchi et al. (1995, 1997) have demonstrated that, in the absence of NA, two FP-HA-sialidated oligosaccharides attached to the asparagine residues at positions 123 and 149, which are in the vicinity of the receptor site, inhibit binding of FP-HA to sialic acid-containing receptors and, thus, its haemagglutinating activity. In other words, although FP-HA is a wild-type molecule, receptor-binding function is inhibited in the absence of NA. Thus, it is logical to postulate that the blockage of the receptor-binding site is the reason why FP-HA can be incorporated into retrovirus particles in the absence of NA. The relative positions of the attached N-linked oligosaccharides in Aichi-HA are different (Fig. 1). The equivalent of that attached to FP-HA N123 is missing and the equivalent of that attached to N149 is shifted by a few amino acids. These Aichi-HA oligosaccharides apparently do not block sialic acid-containing receptor binding of the Aichi-HA protein.

The principles concerning virus particle release and glycoprotein incorporation, which have been learnt from these analyses with influenza virus HA, are, in fact, more generally applicable. An example would be the trapping of HIV on the surface of dendritic cells by DC-SIGN, a process of pronounced functional importance in vivo (Geijtenbeek et al., 2000). Furthermore, in a scenario similar to that described in this study, incorporation of HIV-Env into released particles was blocked by interactions with the cellular receptor CD4, a situation that, in this case, was reversible by coexpression of HIV-Nef and -Vpu (Lama et al., 1999). These considerations should be kept in mind when attempts aimed at the incorporation of a particular glycoprotein into, for example, retrovirus vector particles are made.
growth factor receptor into human immunodeficiency virus-like particles: insight into the processes governing glycoprotein incorporation into retroviral particles. *Journal of Virology* 73, 9294–9302.


Received 8 March 2001; Accepted 25 June 2001